AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01266681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amiodarone
Description: Visit One:. Once consent is given patarticipants will be randomised into either group and instructed and prescribed the drug as appropriate.~Visit Two: Patients will attend for routine cardioversion. This is performed by an experienced CCU nurse as per normal protocol. Patients will also undergo an ECG, and fill in symptom and quality of life (QoL) questionnaires.~Visit Three: Patients will attend a routine outpatient appointment 6 weeks post cardioversion. They will undergo ECG and fill in symptom and QoL questionnaires~Visit Four: Participants will attend at 12 weeks for ECG, symptom and QoL questionnaires~Visit Five: Participants will attend at 24 weeks for ECG, symptom and QoL questionnaires~Visit Six: Participants will attend at 36 weeks for ECG, symptom and QoL questionnaires~Visit Seven: Participants will attend at 52 weeks for ECG, symptom and QoL questionnaires. Participants will then be followed up as per protocol by their consultant cardiologist.
Study NCT01266681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronedarone
Description: Visit One: patarticipants will be randomised into either group and instructed and prescribed the drug as appropriate.~Visit Two: Patients will attend for routine cardioversion. This is performed by an experienced CCU nurse as per normal protocol. Patients will also undergo an ECG, and fill in symptom and quality of life (QoL) questionnaires.~Visit Three: Patients will attend a routine outpatient appointment 6 weeks post cardioversion. They will undergo ECG and fill in symptom and QoL questionnaires~Visit Four: Participants will attend at 12 weeks for ECG, symptom and QoL questionnaires~Visit Five: Participants will attend at 24 weeks for ECG, symptom and QoL questionnaires~Visit Six: Participants will attend at 36 weeks for ECG, symptom and QoL questionnaires~Visit Seven: Participants will attend at 52 weeks for ECG, symptom and QoL questionnaires. Participants will then be followed up as per protocol by their consultant cardiologist.
Study NCT00003453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Stage IV Adrenal Gland Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT01818583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride
Study NCT01818583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose 50 MG/ML
Study NCT02129270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine HCl 2% .
Description: comparison of different dosages of drug
Study NCT02129270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine HCl 1%
Description: comparison of different dosages of drug
Study NCT02299180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP
Study NCT04129216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: 10mg administered daily. Patients take this drug for 2-6 weeks
Study NCT04129216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5mg is administered daily. Patients take this drug for 2-6 weeks
Study NCT04129216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25mg is administered daily. Patients take this drug for 2-6 weeks.
Study NCT04129216 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blueprint
Description: studies the genomics of the tumor and tumor behavior
Study NCT04129216 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mammaprint
Description: studies the genomics of the tumor
Study NCT03007966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25%
Description: Administered as part of the local anesthetic mixture
Study NCT03007966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Description: Administered as part of the local anesthetic mixture
Study NCT03007966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine 1:200k
Description: Administered as part of the local anesthetic mixture
Study NCT03007966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine 1:200k
Description: Administered as part of the local anesthetic mixture
Study NCT03007966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine 1.66mcg/cc
Description: Administered as part of the local anesthetic mixture
Study NCT03007966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine 1.66mcg/cc
Description: Administered as part of the local anesthetic mixture
Study NCT02848287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 1\*2 gauze is soaked with 5 cc of 0.9 % normal saline, applied in tonsillar fossae for 3 min, then removed.
Study NCT02848287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: 1\*2 gauze is soaked with 5 cc of 0.75% ropivacaine, applied in tonsillar fossae for 3 min, then removed.
Study NCT00371683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin + Placebo
Description: Syringes + tablets, Subcutaneous + Oral, 30mg, twice daily, 12 day treatment period
Study NCT02372578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3662
Description: oral
Study NCT02372578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: oral
Study NCT02372578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3662 placebo
Description: oral
Study NCT02372578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASP3662 placebo
Description: oral
Study NCT02372578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASP3662 placebo
Description: oral
Study NCT00371683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban + Placebo
Description: Tablet + Syringes, Oral + subcutaneous, 2.5 mg, twice daily, 12 day treatment period
Study NCT04717245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Promestriene Vaginal
Description: Patients used promestriene vaginal cream for 3 months. The use was recommended to be diary fot the first 2 weeks, and then, repeat every 3 days.
Study NCT04717245 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 LASER
Description: LASER treatment with fractional CO2 Laser was performed in 3 sessions with intervals of 4 weeks between them. Before each session, the patients underwent specular examination.~Fractional CO2 LASER was applied following these parameters, fixed in all sessions: vagina wall - power40 W, dwel time 1000 mcs, spacing 1000 mcm and stack 2, vestibule - power 10W, dwel time 500mcs, spacing 300mcg and satck 1
Study NCT04717245 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microablative Fractional radiofrequency
Description: Microablative fractional radiofrequency was performed with the equipment calibrated in FRAXX mode, 45W, Low Energy program 40 milliseconds in the vaginal and introitus wall. Lidocaine spray was applied to vaginal introitus before the procedure.~The patient was in the gynecological position. The vaginal speculum was placed and, afterwards, the vaginal antisepsis was performed with aqueous chlorhexidine and cleaning with 0.9% saline solution.~All liquid contents were wiped off before beginning the procedure. The fractured tip will be pressed lightly and as perpendicular as possible into the vulvar or vaginal surface, ensuring full contact of all points in the tissue, starting at the lateral vaginal walls and from the proximal to the distal third.
Study NCT00232544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telecommunications system
Description: The telecommunications system is designed to improve patient adherence with prescribed positive airway pressure.
Study NCT00232544 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TLC-Control
Description: A TLC system for providing general health education
Study NCT00672191 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-004
Description: HIV-1 Immune Therapy
Study NCT02372578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin placebo
Description: oral
Study NCT02372578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pregabalin placebo
Description: oral
Study NCT02076607 — intervention group
Intervention type: PROCEDURE
Intervention: Arthrodesis
Description: Posterior approach to toracolumbar spine fusion.
Study NCT02076607 — intervention group
Intervention type: DEVICE
Intervention: Brace
Description: Toracolumbar imobilization
Study NCT01421017 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Study NCT01421017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Study NCT01421017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT00443417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SK-PC-B70M
Description: dosage, frequency
Study NCT00443417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SK-PC-B70M
Description: dosage, frequency
Study NCT02401685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Description: Adjuvant therapy will include chemotherapy and/or endocrine therapy for all women, and radiotherapy to breast or chest wall if indicated. Human epidermal growth factor receptor 2 (HER2) targeted treatment may also be administered when indicated.
Study NCT02401685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant therapy
Description: Adjuvant therapy will include chemotherapy and/or endocrine therapy for all women, and radiotherapy to breast or chest wall if indicated. Human epidermal growth factor receptor 2 (HER2) targeted treatment may also be administered when indicated.
Study NCT02401685 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary treatment
Description: Axillary treatment can be axillary node clearance or axillary radiotherapy as per local guidelines.
Study NCT04820244 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03041948 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ilioinguinal/iliohypogastric nerve block
Description: See arm description
Study NCT03041948 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal-epidural nerve block
Description: See arm description
Study NCT03041948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: See arm description
Study NCT03041948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: See arm description
Study NCT03041948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: See arm description
Study NCT03041948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: See arm description
Study NCT03041948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: See arm description
Study NCT03041948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: See arm description
Study NCT03041948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: See arm description
Study NCT03041948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: See arm description
Study NCT03041948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: See arm description
Study NCT03041948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: See arm description
Study NCT03041948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: See arm description
Study NCT03041948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: See arm description
Study NCT03041948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: See arm description
Study NCT03041948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: See arm description
Study NCT03041948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: See arm description
Study NCT03041948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: See arm description
Study NCT01364584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Subcutaneous injection 2.5 micrograms (mcg) to 10 mcg twice per day (BID)
Study NCT01364584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection 2.5 mcg-10 mcg BID
Study NCT01599975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long acting methylphenidate
Description: Treatment with long-acting methylphenidate, 36 mg a day as 2 tablets of 18 mg each.
Study NCT01599975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long acting methylphenidate
Description: 18 mg tablets, 2 tablets daily by mouth x 2 weeks, then washout x 2 weeks, then crossover to 2 tablets of matched placebo x 2 weeks.
Study NCT01599975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: 2 tablets of matched placebo daily by mouth
Study NCT00793195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%
Description: Dosing will be formulated according to a Nomogram for Parenteral Nutrition (PN) composition, which takes into account the percentage of the subject's caloric intake consumed parenterally. PN solution will be infused continuously over 12-24 hours by infusion pump, and the duration each day will depend on the enteral tolerance of the child. PN shall not be discontinued, unless the patient is taking 95% of calories enterally with good growth as evidence by appropriate weight gain. Subjects will receive the trial lipid for a total duration of 12 weeks or if they develop a serum conjugated bilirubin (sustained for 7 days) of 100 umol/l (6mg/dl) or full enteral tolerance prior to this end-point. Once the trial lipid is discontinued, in the event that PN is continued, subjects will return to the standard lipid preparation. A final follow-up data-point will be collected 4 weeks after the trial lipid is stopped.
Study NCT00793195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOFlipid 20%
Description: Dosing will be formulated according to a Nomogram for Parenteral Nutrition (PN) composition, which takes into account the percentage of the subject's caloric intake consumed parenterally. PN solution will be infused continuously over 12-24 hours by infusion pump, and the duration each day will depend on the enteral tolerance of the child. PN shall not be discontinued, unless the patient is taking 95% of calories enterally with good growth as evidence by appropriate weight gain. Subjects will receive the trial lipid for a total duration of 12 weeks or if they develop a serum conjugated bilirubin (sustained for 7 days) of 100 umol/l (6mg/dl) or full enteral tolerance prior to this end-point. Once the trial lipid is discontinued, in the event that PN is continued, subjects will return to the standard lipid preparation. A final follow-up data-point will be collected 4 weeks after the trial lipid is stopped.
Study NCT05161416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bubble Blowing
Description: Active Distraction Methods
Study NCT05161416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cartoon Watching
Description: Passive Distraction Methods
Study NCT04220216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: H4H fitness program
Description: 4 weekly, 1 hour exercise sessions
Study NCT01410890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alglucosidase alfa
Description: Intravenous (IV) infusion of 20mg/kg body weight every other week (qow)
Study NCT05001334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kangaroo care training
Description: During perinatal period, mothers are given extra training (other than routine newborn care) about kangaroo care. Baby-mother diad is called for weight check-ups.
Study NCT03573934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-2
Description: GLP-2
Study NCT03573934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP
Description: GIP
Study NCT03573934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-2+GIP
Description: GLP-2+GIP
Study NCT03573934 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03932877 — intervention group
Intervention type: OTHER
Intervention: MMP-14 and s-ENG levels
Description: Venous blood sampled from the antecubital veins for measuring the serum concentration of MMP-14 and s-ENG levels. The serum MMP-14 and s-ENG levels measured using commercially available reagent kits, which is produced to detect human MMP-14 and s-ENG levels (Rel Assay Diagnostics Gaziantep, Turkey). The MMP-14 and s-ENG levels measurements were performed in accordance with the company's protocol.
Study NCT02984488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single visits
Description: Endodontic treatment is done and completed in a single visit using protaper next rotary system.
Study NCT02984488 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: two visits
Description: Endodontic treatment is done and completed in two visits using protaper next rotary system.
Study NCT04053257 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hand hygiene compliance observation with video camera surveillance system and performance feedback of the HH rates to HCWs
Description: Intervention:~We will report baseline HH compliance rates and HAI rates to HCWs during a meeting where all HCWs are present. During this meeting we will remind major infection control measures, give examples of common mistakes they made without violating personal privacy rights of HCWs and patients.
Study NCT03976258 — intervention group
Intervention type: DRUG
Intervention: buprenorphine/naloxone
Description: This is an observational study. Buprenorphine/naloxone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
Study NCT03976258 — intervention group
Intervention type: DRUG
Intervention: Methadone
Description: This is an observational study. Methadone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
Study NCT03976258 — intervention group
Intervention type: DRUG
Intervention: Naltrexone Injection
Description: This is an observational study. Naltrexone injection for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
Study NCT03976258 — intervention group
Intervention type: DRUG
Intervention: Heroin
Description: This is an observational study. Participants using heroin will be enrolled into this group.
Study NCT04493996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: The cognitive training involves a standardized, paper-and-pencil-based cognitive training that will be performed by the patients at home for approximately 40 minutes per day over a preoperative period of 2-3 weeks
Study NCT04344223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balance Shoe
Description: Use of experimental balance shoes for carrying out the tests along the three sessions and one of the two familiarization phases
Study NCT04344223 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Personal Shoe
Description: Use of Personal shoes (the same for each session) for carrying out the tests along the three sessions and one of the two familiarization phases
Study NCT04257201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yellow Oyster -- 84 g
Description: Participants will consume the standardized test day salad plus 84 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
Study NCT04257201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yellow Oyster -- 168 g
Description: Participants will consume the standardized test day salad plus 168 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
Study NCT04257201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White button -- 84 g
Description: Participants will consume the standardized test day salad plus 84 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
Study NCT04257201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White button -- 168 g
Description: Participants will consume the standardized test day salad plus 168 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
Study NCT04257201 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will consume the standardized test day salad only
Study NCT02690181 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS Trivalent Vaccine
Description: Administration of lyophilized formulation of a GBS trivalent vaccine containing 5 µg of each polysaccharide capsules from serotypes Ia, Ib, and III of Group B Streptococcus conjugated to CRM-197 .